相似文献
1
GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans.
Hypertension. 2021 Sep;78(4):1092-1102. doi: 10.1161/HYPERTENSIONAHA.121.17659. Epub 2021 Aug 30.
2
Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor.
Br J Clin Pharmacol. 2016 May;81(5):971-9. doi: 10.1111/bcp.12855. Epub 2016 Jan 17.
3
Discovery of soluble epoxide hydrolase inhibitors through DNA-encoded library technology (ELT).
Bioorg Med Chem. 2021 Jul 1;41:116216. doi: 10.1016/j.bmc.2021.116216. Epub 2021 May 13.
4
The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells.
Prostaglandins Other Lipid Mediat. 2022 Feb;158:106604. doi: 10.1016/j.prostaglandins.2021.106604. Epub 2021 Dec 15.
5
Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice.
J Cardiovasc Pharmacol. 2013 Apr;61(4):291-301. doi: 10.1097/FJC.0b013e31827fe59c.
6
Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.
Chest. 2017 Mar;151(3):555-563. doi: 10.1016/j.chest.2016.10.058. Epub 2016 Nov 21.
7
A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage.
Neurocrit Care. 2022 Jun;36(3):905-915. doi: 10.1007/s12028-021-01398-8. Epub 2021 Dec 6.
8
In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor.
Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31. doi: 10.1016/j.prostaglandins.2013.02.001. Epub 2013 Feb 19.
9
Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue.
J Biol Chem. 2013 May 17;288(20):14189-14199. doi: 10.1074/jbc.M113.458414. Epub 2013 Apr 10.
10
Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.
PLoS One. 2019 Apr 19;14(4):e0215033. doi: 10.1371/journal.pone.0215033. eCollection 2019.
引用本文的文献
1
Intersecting Pathways of Inflammation, Oxidative Stress, and Atherogenesis in the Evaluation of CKD: Emerging Biomarkers PCSK9, EPHX2, AOPPs, and TBARSs.
Life (Basel). 2025 Aug 13;15(8):1287. doi: 10.3390/life15081287.
2
Structure-Based Design of PROTACS for the Degradation of Soluble Epoxide Hydrolase.
J Med Chem. 2025 Jul 10;68(13):13728-13749. doi: 10.1021/acs.jmedchem.5c00552. Epub 2025 Jun 18.
3
Structure-Based Design and Optimization Lead to the Identification of a Novel Potent sEH Inhibitor with PPARγ Partial Agonist Activity against Inflammatory and Metabolic-Related Diseases.
J Med Chem. 2025 Apr 24;68(8):8729-8767. doi: 10.1021/acs.jmedchem.5c00402. Epub 2025 Apr 4.
4
Inhibition of soluble epoxide hydrolase ameliorates cerebral blood flow autoregulation and cognition in alzheimer's disease and diabetes-related dementia rat models.
Geroscience. 2025 Feb 4. doi: 10.1007/s11357-025-01550-8.
5
-Active Soluble Epoxide Hydrolase-Targeting PROTACs with Improved Potency and Stability.
ACS Med Chem Lett. 2024 Oct 3;15(11):1891-1898. doi: 10.1021/acsmedchemlett.4c00357. eCollection 2024 Nov 14.
6
Inhibition of Soluble Epoxide Hydrolase Ameliorates Cerebral Blood Flow Autoregulation and Cognition in Alzheimer's Disease and Diabetes-Related Dementia Rat Models.
bioRxiv. 2024 Aug 31:2024.08.30.610540. doi: 10.1101/2024.08.30.610540.
7
Encoding and display technologies for combinatorial libraries in drug discovery: The coming of age from biology to therapy.
Acta Pharm Sin B. 2024 Aug;14(8):3362-3384. doi: 10.1016/j.apsb.2024.04.006. Epub 2024 Apr 10.
8
Evolution of chemistry and selection technology for DNA-encoded library.
Acta Pharm Sin B. 2024 Feb;14(2):492-516. doi: 10.1016/j.apsb.2023.10.001. Epub 2023 Oct 11.
9
Soluble epoxide hydrolase inhibitors for smoking-associated inflammatory lung diseases and chronic obstructive pulmonary disease: a meta-analytical systematic review of preclinical and clinical studies.
Am J Transl Res. 2023 Nov 15;15(11):6649-6659. eCollection 2023.
10
Small-molecule discovery through DNA-encoded libraries.
Nat Rev Drug Discov. 2023 Sep;22(9):699-722. doi: 10.1038/s41573-023-00713-6. Epub 2023 Jun 16.
本文引用的文献
1
Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans.
Diabetologia. 2017 Jun;60(6):1066-1075. doi: 10.1007/s00125-017-4260-0. Epub 2017 Mar 28.
2
Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.
Chest. 2017 Mar;151(3):555-563. doi: 10.1016/j.chest.2016.10.058. Epub 2016 Nov 21.
3
Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor.
Br J Clin Pharmacol. 2016 May;81(5):971-9. doi: 10.1111/bcp.12855. Epub 2016 Jan 17.
4
Oxidative stress in chronic vascular disease: From prediction to prevention.
Vascul Pharmacol. 2015 Nov;74:23-37. doi: 10.1016/j.vph.2015.09.003. Epub 2015 Sep 10.
5
The Epoxyeicosatrienoic Acid Pathway Enhances Hepatic Insulin Signaling and is Repressed in Insulin-Resistant Mouse Liver.
Mol Cell Proteomics. 2015 Oct;14(10):2764-74. doi: 10.1074/mcp.M115.049064. Epub 2015 Jun 12.
6
CYP2J2 and EETs protect against lung ischemia/reperfusion injury via anti-inflammatory effects in vivo and in vitro.
Cell Physiol Biochem. 2015;35(5):2043-54. doi: 10.1159/000374011. Epub 2015 Mar 30.
7
Epoxyeicosatrienoic acids, hypertension, and kidney injury.
Hypertension. 2015 Mar;65(3):476-82. doi: 10.1161/HYPERTENSIONAHA.114.03585. Epub 2015 Jan 12.
8
Epoxyeicosatrienoic acids mediate insulin-mediated augmentation in skeletal muscle perfusion and blood volume.
Am J Physiol Endocrinol Metab. 2014 Dec 15;307(12):E1097-104. doi: 10.1152/ajpendo.00216.2014. Epub 2014 Oct 21.
9
Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans.
Prostaglandins Other Lipid Mediat. 2014 Oct;113-115:38-44. doi: 10.1016/j.prostaglandins.2014.08.001. Epub 2014 Aug 28.
10
The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt.
J Biol Chem. 2014 Feb 14;289(7):4377-86. doi: 10.1074/jbc.M113.508416. Epub 2013 Dec 24.
Zotero 插件